Iscador Qu as Supportive Treatment in Colorectal Cancer (Union International Cancer Control, UICC Stages II-IV)
Launched by IFAG AG · Oct 6, 2011
Trial Information
Current as of July 24, 2025
Unknown status
Keywords
ClinConnect Summary
see summary
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Confirmed diagnosis of colorectal cancer, UICC stage II-IV
- • Age between 18 (Austria: 19) and 85 years
- • No previous malign tumor
- • Surgical resection of the tumor if indicated
- • (Post-operative) conventional oncological therapy and measurements, or passive after-care ("best care")
- • Follow-up for several years feasible
- • Patient gives written consent to use the anonymized date for evaluation
- Exclusion Criteria:
- • Anal cancer
- • Other Iscador® sorts than Qu in the test group
- • Other mistletoe preparations in the test group
- • Any mistletoe preparation in the control group
- • Non-oncological immunomodulating, -stimulating or -suppressive drugs (e.g. Echinacea, interferons, Polyerga®, BCG, azathioprine). Allowed are approved tumor inhibiting immuno- or targeted therapies (e.g. bevacizumab, cetuximab) and tumor specific vaccines
- • HIV infection, Aids, organ transplantation
- • High-dose systemic glucocorticoids
- • Contraindications for Iscador® Qu (allergy against mistletoe, acute inflammatory disease or fever \> 38.5°C, active tuberculosis, hyperthyreosis with not-adjusted metabolism, primary brain or spinal tumor, brain metastases)
- • Known mistletoe intolerance
- • Patients participating in another clinical study with non-approved substances
About Ifag Ag
Ifag AG is a leading clinical trial sponsor specializing in the development and management of innovative therapies across various therapeutic areas. With a commitment to advancing medical science, Ifag AG collaborates with research institutions and healthcare professionals to conduct rigorous clinical trials that adhere to the highest ethical and regulatory standards. The company leverages its extensive expertise and state-of-the-art technology to facilitate efficient trial execution, ensuring robust data collection and analysis. Through its dedication to improving patient outcomes, Ifag AG plays a pivotal role in bringing groundbreaking treatments from the laboratory to the market.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Vienna, , Austria
Vienna, , Austria
Bochum, , Germany
Fulda, , Germany
Halle (Saale), , Germany
Herdecke, , Germany
Munich, , Germany
Soest, , Germany
Ulm, , Germany
Patients applied
Trial Officials
Thomas Seufferlein, Prof. M.D.
Principal Investigator
University Clinic Halle (Saale)
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials